Drug Interactions between Bydureon BCise and Ozempic
This report displays the potential drug interactions for the following 2 drugs:
- Bydureon BCise (exenatide)
- Ozempic (semaglutide)
Interactions between your drugs
No interactions were found between Bydureon BCise and Ozempic. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Bydureon BCise
A total of 373 drugs are known to interact with Bydureon BCise.
- Bydureon bcise is in the drug class GLP-1 Agonists (Incretin Mimetics).
- Bydureon bcise is used to treat Type 2 Diabetes.
Ozempic
A total of 273 drugs are known to interact with Ozempic.
- Ozempic is in the drug class GLP-1 Agonists (Incretin Mimetics).
- Ozempic is used to treat the following conditions:
Drug and food interactions
exenatide food
Applies to: Bydureon BCise (exenatide)
ADJUST DOSING INTERVAL: Exenatide slows gastric emptying and may reduce the extent and rate of absorption of concomitantly administered oral medications. When acetaminophen 1000 mg was administered simultaneously with exenatide 10 mcg and also one hour, 2 hours, and 4 hours after exenatide injection, acetaminophen systemic exposure (AUC) was decreased by 21%, 23%, 24%, and 14%, respectively; peak plasma concentration (Cmax) was decreased by 37%, 56%, 54%, and 41%, respectively; and time to peak plasma concentration (Tmax) was increased from 0.6 hours in the control period to 0.9 hours, 4.2 hours, 3.3 hours, and 1.6 hours, respectively. These values were not significantly changed when acetaminophen was given one hour before exenatide injection.
MANAGEMENT: Concomitantly administered oral medications that are dependent on threshold concentrations for efficacy (e.g., antibiotics, contraceptives) or that require rapid gastrointestinal absorption (e.g., hypnotics, pain medications) should be administered at least 1 hour before exenatide. If such medications are to be administered with food, patients should be advised to take them with a meal or snack when exenatide is not administered.
References (1)
- (2005) "Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc
semaglutide food
Applies to: Ozempic (semaglutide)
ADJUST DOSING INTERVAL: Taking oral semaglutide with food, beverage, or other oral medications may alter semaglutide absorption and exposure. In a controlled study with healthy volunteers, limited or no measurable semaglutide exposure was observed in subjects that were fed 30 minutes prior to taking oral semaglutide, while all subjects that fasted overnight and 30 minutes after the oral semaglutide dose had measurable semaglutide exposure. Area under the curve (AUC) and semaglutide peak plasma concentration (Cmax) were approximately 40% greater in subjects that fasted compared to those who did not. AUC and Cmax were also increased with a post-dose fasting period greater than 30 minutes.
MANAGEMENT: It is recommended that oral semaglutide be taken 30 minutes before the first food, beverage, or other oral medications of the day with no more than 4 ounces of plain water to ensure its efficacy. Fasting longer than 30 minutes after the oral semaglutide dose may lead to increased gastrointestinal side effects including nausea, vomiting, or diarrhea.
References (4)
- (2024) "Product Information. Rybelsus (semaglutide)." Novo Nordisk Pharmaceuticals Inc
- (2024) "Product Information. Rybelsus (semaglutide)." Novo Nordisk Canada Inc
- (2024) "Product Information. Rybelsus (semaglutide)." Novo Nordisk Ltd
- Baekdal TA, Breitschaft A, Donsmark M, Maarbjerg SJ, Sondergaard FL, Borregaard J (2021) "Effect of various dosing conditions on the pharmacokinetics of oral semaglutide, a human glucagon-like peptide-1 analogue in a tablet formulation" Diabetes Ther, 12, p. 1915-27
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
Incretin-based therapies
Therapeutic duplication
The recommended maximum number of medicines in the 'incretin-based therapies' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'incretin-based therapies' category:
- Bydureon BCise (exenatide)
- Ozempic (semaglutide)
Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.